2.2.1. Treatment Response According to mPERCIST and RECIST

After 3.7 ± 1.0 months, data of 19 patients were available for response evaluation. Of those 19 patients, 12/19 patients showed disease control (DC) according to mPERCIST and 14/19 showed DC according to RECIST, whereas 7/19 patients showed progressive disease (PD) according to mPERCIST and 5/19 patients according to RECIST. None of the enrolled patients showed complete response (CR) in morphological evaluation (RECIST), though 3 patients showed CR in a metabolic assessment (see Figure 1a).

**Figure 1.** Tumor response evaluation by mPERCIST and RECIST criteria at 3 month (**a**) and 6 month (**b**) follow-up imaging. mPERCIST, modified Positron Emission Tomography Response Criteria In Solid Tumors; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

After 5.7 ± 1.4 months, 22 patients were evaluated. Compared to baseline, more patients showed PD (mPERCIST/RECIST: 11/6), but 2 patients indicated CR according to mPERCIST and one patient according to RECIST (see Figure 1b).

For both evaluation time-points, the majority of patients were rated SD in morphological evaluation (3 months: *n* = 12, 6 months: *n* = 12), while there was more heterogeneity in metabolic treatment response, with most patients presenting with PD. Details of treatment response at 3 and 6 months are presented in Figure 1 and single-patient course of disease are summarized in Table S2 in the supplemental file.
